Harnessing the power of light to fight cancer

February 4, 2016 by Christina Sumners

Immunotherapy is one of the hottest emerging areas of cancer research. After all, using the body's own cells to fight cancer can be more effective and less invasive than flooding the entire system with toxic chemicals.

Yubin Zhou, Ph.D., assistant professor at the Center for Translational Cancer Research at the Texas A&M Health Science Center Institute of Biosciences & Technology, is studying how to use to control the immune system and induce it to fight cancer.

"Although neuroscientists have been using light to stimulate neurons for years, this is the first time the technique, called optogenetics, has been used in the immune system," Zhou said. In neuroscience, the process involves genetically engineering cells to produce proteins from light-sensitive microbes and results in nerve cells that will either send—or stop sending—nerve impulses when they are exposed to a particular color of light. "Neuroscientists have learned a lot about brain circuits using the technique," Zhou said, "and now researchers in many other fields are giving it a try."

Zhou and his collaborators have modified the technique for the immune system. It wasn't easy: unlike nerve cells, don't use tiny electrical impulses to communicate. Additionally, immune cells are located deep in the and are constantly moving around, so getting the light to them can be difficult.

The development took some ingenuity and cooperation. "We collaborated with Dr. Gang Han at the University of Massachusetts Medical School who does bionanotechnology and photomedicine development," Zhou said. "Together, we were able to combine state-of-the-art optogenetic approaches with cutting edge nanotechnology." Called optogenetic immunomodulation, their method was featured in a recently published article in eLife.

"This work was driven by talented scientists in the lab: graduate students Lian He and Peng Tan and postdoctoral research fellow Guolin Ma, Ph.D.," Zhou said, "who fearlessly undertook this daunting project and overcame all the challenging obstacles to make this technique into reality."

With this method, the researchers can control the action of immune cells and "instruct" them to kill cancerous tumor cells. They use a near-infrared laser beam, which can penetrate deep—in this context, deep means a centimeter or two—into the tissue, where a nanoparticle turns the near-infrared light into blue light, and that directs the activity of genetically engineered immune cells. "We are able to wirelessly control the action of immune cells buried deep in tissue," Zhou said.

The team genetically engineered immune cells so that a calcium gate-controlling protein became light sensitive. When they are exposed to the blue light emitted by the nanoparticle, their calcium ion gates open. When the light is turned off, the gates close. More light leads to a greater flow of calcium, so the researchers are able to finely tune the calcium-dependent actions of immune cells to fight against invading pathogens or tumor cells.

When an animal tumor model was injected with both the nanoparticle and the light-sensitive genetically engineered immune cells, the near-infrared laser beam caused calcium channels to open, which boosted an immune response to aid the killing of cancer cells. "The technique reduced tumor size and metastasis, so there are lots of applications," Zhou said.

One advantage of this method is that it only activates a certain type of immune cell, the dendritic cell or T-cell, and only in one part of the body, near the draining lymph nodes or tumor, which helps cut down on the system-wide side effects often seen with chemotherapy. It's also light-tunable, non-invasive and has great temporal resolution—in other words, it can be turned on when it is needed and turned off when it is not.

The implications of the research are far-reaching. "Other scientists will likely use the technique to help them study immune, heart and other types of cells that use calcium to perform their tasks," Zhou said. "It's quite a cool technology. With these tools, we can now not only answer fundamental questions of science that we never could before but also translate it into the clinic for disease intervention."

In parallel, the Zhou lab has been applying this technique to establish a way to screen potential cancer drugs more effectively. "If successful," Zhou said, "all these efforts would remarkably improve the current cancer immunotherapies by personalizing the treatment to exactly where and when it is needed, while reducing side effects."

Explore further: Optogenetic technology developed at UMMS uses light to trigger immunotherapy

Related Stories

Optogenetic technology developed at UMMS uses light to trigger immunotherapy

January 25, 2016
A new optogenetic technology developed by scientists at the University of Massachusetts Medical School and Texas A&M Health Science Center Institute of Biosciences & Technology, called optogenetic immunomodulation, is capable ...

Researchers identify way radiation may fight cancer cells escaping immune system

February 2, 2016
A team of Georgia State University researchers is fighting cancers using a combination of therapies and recently found ways that radiation could maximize responses to novel immune-based therapeutic approaches to fight cancer.

First-ever recording of the battle between a tumor cell and an immune cell

December 9, 2015
Metastasizing cancer cells do not destroy tissue, but crawl along the paths that have already been created by blood vessels, nerve bundles and other tissues. However, immune cells that fight the cancer cells take those same ...

Cancer cells hijack glucose, alter immune cells

November 2, 2015
When cancer cells compete with immune cells for glucose, the cancer wins. As a result, the immune T cells are not healthy and don't have the weapons to kill the cancer.

Cells' lack of glucose dulls immune system's ability to fight cancers

September 25, 2015
One of scientists' great hopes in fighting cancer is the immune system. If the same cells that battle viruses and other invaders recognize a tumor as foreign, the expectation is that they should be able to attack the cancer.

A shift in energy processing pathways occurs in immune cells that tolerate pathogens

September 25, 2015
A fundamental metabolic shift in immune system cells has been identified by A*STAR researchers as responsible for whether they attack or tolerate disease recognized by our immune defenses. If the cells do not respond correctly, ...

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.